Evidence map›Paper›PMID 26450933›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2015

AKI in Children Hospitalized with Nephrotic Syndrome.

Michelle N Rheault, Lei Zhang, David T Selewski, Mahmoud Kallash, Cheryl L Tran, Meredith Seamon, Chryso Katsoufis, Isa Ashoor, Joel Hernandez, Katarina Supe-Markovina and 12 more

Abstract readMulticenter Study
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Guideline
  5. Nephrotic Syndrome: Current Management.Indian journal of pediatrics · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Michelle N RheaultDue to the number of contributing authors, the affiliations are provided in the Supplemental Material. rheau002@umn.edu.
Lei ZhangDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
David T SelewskiDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Mahmoud KallashDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Cheryl L TranDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Meredith SeamonDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Chryso KatsoufisDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Isa AshoorDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Joel HernandezDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Katarina Supe-MarkovinaDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Cynthia D'Alessandri-SilvaDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Nilka DeJesus-GonzalezDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Tetyana L VasylyevaDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Cassandra FormeckDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Christopher WollDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Rasheed GbadegesinDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Pavel GeierDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Prasad DevarajanDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Shannon L CarpenterDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Bryce A KerlinDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
William E SmoyerDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Midwest Pediatric Nephrology Consortium

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
Proteomics CoreP50DK096418 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI DEVARAJAN, PRASAD · 2012 to 2021
$8.4M
Gene Discovery in Autosomal Dominant Focal Segmental GlomerulosclerosisR01DK094987 · NIDDK · DUKE UNIVERSITY · PI GBADEGESIN, RASHEED ADEBAYO · 2012 to 2016
$2.5M
Functional and Phenotypic Characterization of a New FSGS GeneR01DK098135 · NIDDK · DUKE UNIVERSITY · PI GBADEGESIN, RASHEED ADEBAYO · 2014 to 2018
$1.8M
Coagulation Protease Signaling in Glomerular DiseaseK08DK103982 · NIDDK · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI KERLIN, BRYCE ANDREW · 2015 to 2019
$744k
Functional and Phenotypic Characterization of a New FSGS GeneR56DK098135 · NIDDK · DUKE UNIVERSITY · PI GBADEGESIN, RASHEED ADEBAYO · 2013 to 2013
$118k
NCATS NIH HHS UL1 TR000114NIDDK NIH HHS DK094987NIDDK NIH HHS DK098135-01A1NIDDK NIH HHS K08 DK103982NIDDK NIH HHS L40 DK103299NIDDK NIH HHS NIH P50 DK096418NIDDK NIH HHS P50 DK096418NIDDK NIH HHS R01 DK094987NIDDK NIH HHS R01 DK098135NIDDK NIH HHS R56 DK098135
6 · The paper itself

Abstract

BACKGROUND AND

objectivesChildren with nephrotic syndrome can develop life-threatening complications, including infection and thrombosis. While AKI is associated with adverse outcomes in hospitalized children, little is known about the epidemiology of AKI in children with nephrotic syndrome. The main objectives of this study were to determine the incidence, epidemiology, and hospital outcomes associated with AKI in a modern cohort of children hospitalized with nephrotic syndrome. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Records of children with nephrotic syndrome admitted to 17 pediatric nephrology centers across North America from 2010 to 2012 were reviewed. AKI was classified using the pediatric RIFLE definition.

resultsAKI occurred in 58.6% of 336 children and 50.9% of 615 hospitalizations (27.3% in stage R, 17.2% in stage I, and 6.3% in stage F). After adjustment for race, sex, age at admission, and clinical diagnosis, infection (odds ratio, 2.24; 95% confidence interval, 1.37 to 3.65; P=0.001), nephrotoxic medication exposure (odds ratio, 1.35; 95% confidence interval, 1.11 to 1.64; P=0.002), days of nephrotoxic medication exposure (odds ratio, 1.10; 95% confidence interval, 1.05 to 1.15; P<0.001), and intensity of medication exposure (odds ratio, 1.34; 95% confidence interval, 1.09 to 1.65; P=0.01) remained significantly associated with AKI in children with nephrotic syndrome. Nephrotoxic medication exposure was common in this population, and each additional nephrotoxic medication received during a hospitalization was associated with 38% higher risk of AKI. AKI was associated with longer hospital stay after adjustment for race, sex, age at admission, clinical diagnosis, and infection (difference, 0.45 [log]days; 95% confidence interval, 0.36 to 0.53 [log]days; P<0.001).

conclusionsAKI is common in children hospitalized with nephrotic syndrome and should be deemed the third major complication of nephrotic syndrome in children in addition to infection and venous thromboembolism. Risk factors for AKI include steroid-resistant nephrotic syndrome, infection, and nephrotoxic medication exposure. Children with AKI have longer hospital lengths of stay and increased need for intensive care unit admission.

Indexed as

HospitalizationAcute Kidney InjuryAdolescentAge FactorsChildChild, PreschoolDrug-Related Side Effects and Adverse ReactionsFemaleHumansIncidenceInfantLength of StayLinear ModelsMaleMedical RecordsMultivariate Analysisacute kidney injurychilddialysishospitalizationhumansincidencelength of staynephrotic syndromenephrotoxicityrisk factors

Identifiers

PMID26450933
PMCPMC4670770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.